Cancer Family
Liver Epithelial Neoplasm
CI-CAN-00000217Explore in graph →
Non-malignant784 active trials14 approved drugs17 evidence items
- NCIt
- C7106
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000217Explore in graph →
Clinical trials
3,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05498779 | Ablation of Hepatocellular Carcinoma: a Nationwide Study | completed | — | 490 | Rigshospitalet, DenmarkOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01447667 | Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)(MRE) | completed | N/A | 72 | Seoul National University HospitalOTHER | 1 | Nov 22, 2023 |
| NCT01910909 | Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma(SBRT for HCC) | completed | N/A | 56 | Samsung Medical CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04391348 | Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC(PET-HCC01) | completed | N/A | 230 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02279719 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 97 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02460835 | A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma | completed | N/A | 77 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | completed | Phase 2 | 45 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer(STOP-HCC) | completed | N/A | 526 | Boston Scientific CorporationINDUSTRY | 11 | Nov 8, 2023 | clinicaltrials |
| NCT04569799 | Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE(TACE) | completed | Phase 4 | 26 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04555265 | Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation | completed | N/A | 60 | Chinese University of Hong KongOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03702998 | Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population | completed | — | 3,900 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04942665 | Low Dose ICG for Biliary Tract and Tumor Imaging(ICG) | completed | Phase 2 | 60 | University of FloridaOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06013657 | Surgical Resection for Hepatocellular Carcinoma | completed | — | 91 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04920019 | Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery | completed | N/A | 140 | Mahidol UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06005883 | Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring | completed | — | 332 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT00539643 | Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | completed | Phase 2 | 101 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05643391 | Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma(RETOUCH) | completed | N/A | 20 | Erasme University HospitalOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04642547 | Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | completed | N/A | 30 | RenJi HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05291338 | Pharmacogenetic Study in Hepatocellular Carcinoma Patients. | completed | — | 107 | Rehab WeridaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT03347292 | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | completed | Phase 1 | 58 | BayerINDUSTRY | 2 | Jul 25, 2023 | clinicaltrials |
| NCT03572582 | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma(IMMUTACE) | completed | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04975932 | Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study(CHANCE001) | completed | — | 826 | Zhongda HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02424955 | Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation | completed | N/A | 11 | Stanford UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04823754 | Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"(PERCEPTION1) | completed | — | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01890291 | Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.(Immuncell-LC) | completed | — | 162 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT01897610 | Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC | completed | Phase 2 | 40 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02856815 | Safety and Efficacy of "Immuncell-LC" in TACE Therapy | completed | Phase 2 | 76 | GC Cell CorporationINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02513199 | Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 32 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05304572 | Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography | completed | — | 70 | Assiut UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00813293 | Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer | completed | Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05213221 | Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients(CISLD-12) | completed | Phase 2 | 39 | Zhejiang UniversityOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04044313 | HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | completed | Phase 2 | 36 | Shi MingOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04837742 | The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy | completed | N/A | 30 | National Taiwan University HospitalOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT04681274 | Phenotyping Liver Cancer Registry(PHELICAR) | completed | — | 2,429 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03841201 | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | completed | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04641637 | Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC | completed | N/A | 40 | Chinese University of Hong KongOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | TakedaINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04970212 | Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures | completed | — | 65 | Techsomed Medical Technologies LTDINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 28, 2023source: clinicaltrials